Madam Chair, I want to thank the hon. member for the way he presented his questions. He is absolutely correct. The investments we have made, particularly when it comes to vaccines and therapeutics, are designed to support Canadian solutions.
That is why we invested $175 million for AbCellera, a biotech company out of Vancouver that is working on identifying antibodies. Ultimately, it actually identified one antibody for a drug therapy.
That is the type of investment that we are making, which will benefit not only Canadians but many people outside of Canada as well.